Table 4.
Study reference | Type of study | Country | Number of newborns with thyroid dysfunction | Volume of OSCM (Lipiodol) used during mother's HSG | Newborn screening strategy | Number of months between OSCM exposure and conception |
---|---|---|---|---|---|---|
Satoh et al. (2015) [25] | RSa | Japan | 5 out of 212 OSCM HSGs | 10 ml, 20 ml, 20 ml, NR, and NR | TSH-based screening | 1, 1, 2, 3, and 12 |
| ||||||
Li et al. (2018) [29] | PSb | China | None out of 36 OSCM HSGs | NRc | TSH-based screening at 72+ hours | NR |
| ||||||
Van Welie et al. (2020) [28] | RS | The Netherlands | None out of 76 OSCM HSGs | 9 ml (6–11.8) | T4 followed by TSH if necessary | 2.3 (1.1–4.3) |
| ||||||
Our study | RS | New Zealand | None out of 146 OSCM HSGs | NR | TSH-based screening at 48+ hours | 0–6 |
Median 2 | ||||||
IQR (1–3) |
aRS: retrospective study; bPS: prospective study; cNR: not recorded; OSCM: oil-soluble contrast medium; HSG: hysterosalpingography; TSH: thyroid-stimulating hormone; T4: tetraiodothyronine.